GEG-Tech is proud to share that their long-time partner’s publication, The Swiss Institute for Experimental Cancer Research lead by Cathrin Brisken (École Polytechnique Fédérale de Lausanne), on their project in breast cancer. For this project, GEG-tech designed robust and efficient lentiviral vectors to aid in their breast cancer research.
Their latest development has led to the discovery that estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor.
These findings suggest that endocrine therapy may need to be personalized, and that abrogating PR expression can be a therapeutic option.
We are excited to see where GEG-Tech and The Swiss Institute for Experimental Cancer Research’s collaborations can lead to next!
